Sunscreen RV 2457C in Photoinduced CLE
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00470912|
Recruitment Status : Completed
First Posted : May 8, 2007
Last Update Posted : May 8, 2007
Lupus erythematosus (LE) is characterized by a large clinical spectrum, and sunligt is a well established factor in the induction and exacerbation of this disease. In all subsets of LE, skin lesions occur preferentially in sun-exposed areas.
Previous studies have demonstrated that the lesions in LE patients reproduced in controlled experimental conditions. The initial reports suggested that the action spectrum for the LE was in the UVB range (290 to 320 nm), but more recent studies have demonstrated that UVA (320 to 400 nm) can contribute to the induction of LE skin lesions.
Antimalarial agents and topical steroids are the main treatments of chronic LE. The second line therapies include retinoids, sulfones, immunosuppressor agents, systemic corticosteroid and thalidomide. Moreover, patients are advised to avoid sun, to wear sunprotective clothing and to apply sunscreen.
The aim of this study was to assess the efficacy of a sunscreen milk with high protection factor against UV-B and UV-A, used exclusively, in the photoinduced LE.
|Condition or disease||Intervention/treatment||Phase|
|Cutaneous Lupus Erythematosus Skin Lesion Experimental Photoinduction Protective Sunscreen||Drug: sunscreen RV 2547C||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||25 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Photoprotective Effects of the RV 2457C Sunscreen Milk in Photoinduced Cutaneous Lupus Erythematosus|
|Study Start Date :||May 2001|
|Actual Study Completion Date :||February 2002|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00470912
|Heinrich Heine University of Duesseldorf, Depatment of Dermatoly|
|Duesseldorf, NRW, Germany, 40225|
|Principal Investigator:||Annegret Kuhn, MD||Heinrich-Heine University of Duesseldorf, Department of Dermatolgy|